Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Performances as Highly Enriched aNd Interactive Concert eXperiences (PHENICX)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: ICT for Learning and Access to Cultural Resources
Action type: Collaborative project
Countries involved: Spain,Netherlands,Austria,Austria,Netherlands
Call:  (FP7-ICT-2011-9, 2011)
Start date: 2013-02-01
End date: 2016-01-31
Duration (months): 36.0
Total project cost (EUR): 3726543.0
EU funding (EUR): 2800000.0
Participants: 7
Project status: CLOSED

Modern digital multimedia and internet technology have radically changed the ways people find entertainment and discover new interests online, seemingly without any physical or social barriers. Such new access paradigms are in sharp contrast with the traditional means of entertainment. An illustrative example of this is live music concert performances that are largely being attended by dedicated audiences only. The PHENICX project aims at bridging the gap between the online and offline entertainment worlds. It will make use of the state-of-the-art digital multimedia and internet technology to make the traditional concert experiences rich and universally accessible: concerts will become multimodal, multi-perspective and multilayer digital artefacts that can be easily explored, customized, personalized, (re)enjoyed and shared among the users. The main goal is twofold: (a) to make live concerts appealing to potential new audience and (b) to maximize the quality of concert experience for everyone. Scientific objectives of PHENICX are (i) to generate a reliable and effective set of techniques for multimodal enrichment of live music concert recordings suitable for implementation and deployment in real-world situations, and (ii) finding ways to offer the resulting multi-faceted digital artefacts as engaging digital experiences to a wide range of users. The project will establish a methodological framework to map these scientific objectives onto a solid implementation platform that will be developed incrementally and tested in real-life use settings. PHENICX will mainly focus on classical music - a European heritage asset that suffers heavily from an image of inaccessibility to outsider audiences. However, findings from PHENICX will be relevant to live concert situations in any genre. With an innovative technology partner, as well as two authoritative professional music stakeholders in the consortium, the project has strong immediate impact and dissemination potential.

Keywords: music concerts,live performances,multimedia,retrieval,enrichment,quality of experience,context-aware,personalization
Translation of the direct-on-blood PCR-NALFIA system into an innovative near point-of-care diagnostic for malaria (DIAGMAL)

Framework: FP7 — Cooperation
Programme: Health
Destination: Horizontal topics for collaborative projects relevant for the whole of theme health
Action type: Collaborative project
Countries involved: Netherlands,Germany,United Kingdom,Finland
Call:  (FP7-HEALTH-2013-INNOVATION-2, 2013)
Start date: 2013-09-01
End date: 2017-02-28
Duration (months): 42.0
Total project cost (EUR): 3565749.11
EU funding (EUR): 2652374.0
Participants: 5
Project status: CLOSED

Accurate diagnosis of malaria is essential to timely install proper treatment. Current diagnostic methods for malaria have limitations, such as detection limit and problems with antigen persistence after successful treatment (rapid diagnostic tests) or may require technical expertise and equipment (microscopy). Treatment on the basis of clinical symptoms only (fever = malaria) must be abandoned. Molecular diagnostic tests (MDx) could circumvent some of the mentioned limitations, but tests are incompatable with the Point of Care concept as they require sample processing, have a contamination risk and complicated read-out systems. Although Real-Time PCR assays have overcome some of these problems, the need of large and expensive equipment and the inability to perform it directly on blood shows the need to further improvement and simplification of MDx. Building on the successful outcomes of EU FP7 project “MALACTRES”, the current proposal aims to further built on the concept of a direct on blood PCR system combined with a simple read-out system. This concept has the following advantages: - Direct on blood: no DNA extraction or sample processing; - Simple read-out system (black/white), no need for gel electrophoresis or computer. The proof of concept was delivered in laboratory ring trials and field evaluations in Thailand and Burkina Faso. The proposed diagnostic will have the following additional features: - Direct on blood and simple read-out - Closed system: reduced risk of contamination - Stabilizing reagents included: increased shelf life, no cold storage - Cheap, quick, sensitive and specific. It is envisaged that a full marketable product will be available in 36 months. During development the consortium (dominated by SMEs) will also look into possibilities to adapt the developed system to small hand-held PCR devices preferably in combination with solar-power operated or chargeable batteries that further enhances the application of the test in remote settings.

Keywords: diagnostics,point of care tests,malaria
Development of Group B Streptococcal vaccine to alleviate emerging antibiotic resistance through elimination of current prophylactic antibiotic strategies in GBS prevention. (NEOSTREP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,Denmark,Ireland,Denmark
Call:  (FP7-HEALTH-2013-INNOVATION-2, 2013)
Start date: 2013-07-01
End date: 2016-10-31
Duration (months): 40.0
Total project cost (EUR): 7891808.2
EU funding (EUR): 5999172.0
Participants: 4
Project status: CLOSED

The NeoStrep project will develop a novel vaccine against Group B Streptococcal (GBS) infections, responsible for 50% of life-threatening infections in newborns. The aim is to provide a safe and effective alternative to current generally implemented antibiotic prophylaxis. Emergence of clinical isolates of GBS with reduced susceptibility to penicillin (the preferred prophylactic antibiotic) and pattern of genetic mutations in penicillin binding proteins of GBS is identical to that observed in Streptococcus pneumoniae prior to the breakthrough of true widespread penicillin resistance in that pathogen. Combined with already existing resistance to a wide range of other antibiotics, this indicates current GBS antibiotic prophylaxis is highly vulnerable to antibiotic resistance. Emergence of widespread antibiotic resistance threatens to return the incidence of GBS disease to pre-prophylaxis levels with the associated significant increases in health cost and morbidity/mortality caused by infections with resistant GBS. The NeoStrep project aims to eliminate the use of prophylactic antibiotics in GBS prevention and hence the problem of emerging antibiotic resistance in GBS through the development of a GBS vaccine. No approved vaccine currently exists, and one currently in development only covers a subset of clinical serotypes. The NeoStrep vaccine, which is based on a novel fusion protein approach, has a wider serotype coverage (95%) and is much cheaper to manufacture than the other GBS vaccine candidate in development. The vaccine is extensively validated in animal models, and a simple production method has been developed. The objective of the project is therefore to advance the vaccine through cGMP production, tox studies and into clinical trials, with the aim of generating proof of concept in humans by means of immunogenicity, response rate, durability and effect on spontaneous vaginal colonisation.

Keywords: group b streptococcus vaccine emerging antibiotic resistance alternative prophylactic
Cancer Responsiveness Monitoring based on Resistance mutations in CTCs (CAREMORE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Horizontal topics for collaborative projects relevant for the whole of theme health
Action type: Collaborative project
Countries involved: Sweden,Netherlands,Netherlands,Sweden,Denmark
Call:  (FP7-HEALTH-2013-INNOVATION-2, 2013)
Start date: 2013-09-01
End date: 2016-08-31
Duration (months): 36.0
Total project cost (EUR): 7224029.34
EU funding (EUR): 5127632.0
Participants: 5
Project status: CLOSED

Today's treatment of metastatic breast cancer is guided by characterisation of the primary tumour while 90% of deaths due to breast cancer occur as a consequence of metastases. Given important differences in molecular characteristics between metastases and primary tumour tissue, characterization of metastatic tumours instead of the primary tumour may provide better treatment guidance for patients with metastatic disease. Metastatic tumours are however difficult to assess using currently available techniques. We propose to clinically validate molecular methods and develop a clinically validated system for characterization of circulating tumour cells, used as proxies for the metastatic tumour, to guide treatment decisions in women with metastatic breast cancer. Two unique methods will be combined, single cell molecular characterization and improved circulating tumour cell sampling and identification, provided by the participating SMEs. Together with leading academic scientists and one industrial partner, the consortium is ideally suited to evaluate the clinical utility of the proposed methods and to validate the methods in order to reach the final development stage before the product will be introduced to the market, which constitutes a significant commercial potential for the SME-partners in the project.

Keywords: 3. diagnostics (biomarker,diagnostics,stratification) 7. circulating tumour cells
comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN (BELLEROPHON)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,France,Switzerland,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-2, 2013)
Start date: 2013-09-01
End date: 2016-08-31
Duration (months): 36.0
Total project cost (EUR): 7105812.8
EU funding (EUR): 5498829.0
Participants: 4
Project status: CLOSED

Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals. Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA or EMEA, prevention also relies heavily on antimicrobials to which antibiotic resistance is developing. To reduce S. aureus disease burden, and antibiotic use associated with it, BELLEROPHON will design, manufacture, and assess in a Phase I clinical study a novel S. aureus vaccine candidate targeting both the cellular and humoral responses. It is designed to be protective against both MRSA and more sensitive S. aureus strains. The project will rely on 4 key components: i) a recently discovered and highly conserved T-cell inducing antigen individually capable of eliciting substantial protection in mouse models; (ii) a secreted toxin antigen, antibodies against which reduce mortality (Hla); (iii) an innovative, proprietary and potent pro-immunogenic series of tags (IMX313 series) which can be fused to the antigens; (iv) the use of viral vectors, including an innovative and proprietary adenoviral vector (ChAdOx1) and/or new ways to use viral vectors to generate protective immunity (MVA mixed with proteins). We will i) identify the most protective method of combining these components in a manufacturable and clinically deployable manner; ii) manufacture and perform initial human studies of the vaccine; iii) identify additional antigens which might further increase the efficacy of the initial product. Our approach will contribute clinical safety and immunogenicity data for a novel vaccine strategy targeting one of the key bacterial pathogens in man. It will pave the way for rapid progression to phase II studies, and thence to larger phase II/III studies aiming to reduce infection.

Keywords: staphylococcus aureus meticillin-resistant s. aureus (mrsa) vaccine cellular and humoral responses phase i
Cell-based regenerative medicine: new challenges for EU legislation and governance (EUCELLEX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: France,Germany,Hungary,Netherlands,United Kingdom,Austria,Belgium,Canada
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2016-09-30
Duration (months): 36.0
Total project cost (EUR): 559840.8
EU funding (EUR): 500000.0
Participants: 9
Project status: CLOSED

This proposal aims at collecting and analysing facts and figures in order to assess the current legislation on the therapeutic use of somatic cells, and to bridge it with the research infrastructure capacity building. Although EU has adopted 3 Directives on Tissues and cells between 2004 and 2006 to harmonise the procurement, storage and use of cells for therapeutic use in Europe, countries have implemented these directives in very different ways. Furthermore, research has been partially covered by the initial regulation, calling into question the match between regulation and practices that will develop in the near future, in particular with the emergence of European research infrastructures. Finally many changes have occurred in the scientific, legal and institutional environment of cell use, leading to a necessary update of this regulation with regards to its implementation in national legislation and its impact on research practice and innovation. Two domains are at stake: research (infrastructures) and medical practice/public health measures (cells). The therapeutic use of cells is regulated by EU law whereas its research counterpart is mainly depending on national laws and regulations. This gap calls for a coordinated action in order to optimize the translational process, since the full pipeline is not coherently taken into account in current legislations. To achieve these objectives, our project relies on a coherent consortium of experts in the fields of cells therapies, cells banks and translational biomedicine, having strong expertise in law and/ or in governance issues. After 36 months the project will deliver evidence about the contemporary practices around cells and will design a picture of the “market” and its distribution between the public and private sector. The project will thus help the Commission in the regulatory choices covering the use of human cells for therapeutic purposes and to foster the innovation potential of related research activities.

Keywords: eu legislation,human cells,embryonic stem cells,cord blood banks,policies,public-private partnership,ethics
Combined Multi-marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention (ASPRE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Horizontal topics for collaborative projects relevant for the whole of theme health
Action type: Collaborative project
Countries involved: United Kingdom,Israel,Iceland,Germany,Finland
Call:  (FP7-HEALTH-2013-INNOVATION-2, 2013)
Start date: 2013-05-01
End date: 2016-10-31
Duration (months): 42.0
Total project cost (EUR): 7556140.9
EU funding (EUR): 5839800.0
Participants: 5
Project status: CLOSED

Project ASPRE is a commercially led development project that aims to boost translation of the results of PREGENESYS (FP6 EU #37244) into effective applications for prenatal care. PREGENESYS has identified several biomarkers for early (11-13 weeks’ gestation) and effective identification of pregnancies at high risk of developing pre-eclampsia (PE). This disorder affects 2-8% of pregnant women and is a major cause of short- and long-term maternal and perinatal morbidity and mortality. Studies under PREGENESYS using in-vitro research methods suggested that aspirin is the most promising agent for preventing PE. Evidence from small clinical studies has indicated that prophylactic use of low-dose aspirin starting before 16 weeks’ gestation can potentially halve the PE prevalence and its associated complications. Objectives: Widespread clinical implementation of a strategy of screening and prevention of PE: (1) Reduce the prevalence of PE requiring delivery before 37 weeks (preterm PE) by at least 50%, (2) Demonstrate through a large multicentre screening and prevention study the acceptability, uptake and efficacy of first trimester multi-parameter screening of preterm PE and its preventative treatment with aspirin, (3) Develop affordable, automated and reliable methods for high throughput measurement of biomarkers and commercial platforms for PE risk assessment software, (4) Develop management protocols for high risk and low risk pregnancies for PE, (5) Improve education and training of healthcare professionals involved in pregnancy care, (6) Conduct the dissemination and training required to drive clinical acceptance and adoption of multi-parameter PE screening and aspirin treatment. Expected results and impact: Generating a market demand for SME-based newly developed products for PE screening and prevention, including machines, kits and software, thereby transforming research success into economic growth for SMEs and upholding European leadership in perinatal care.

Keywords: pregnancy,screening,first trimester,prevention,placenta,uterine artery doppler,patient history,biomarkers,plgf,pp13,ultrasound,blood pressure,pre-eclampsia,iugr,pregnancy hypertension.
Hanging Drop based automated and parallelized cell technology platform for production and testing (DROPTECH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Horizontal topics for collaborative projects relevant for the whole of theme health
Action type: Collaborative project
Countries involved: Germany,Germany,France,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-2, 2013)
Start date: 2014-02-01
End date: 2017-01-31
Duration (months): 36.0
Total project cost (EUR): 5228090.4
EU funding (EUR): 4051319.0
Participants: 4
Project status: CLOSED

Cell-based screenings are today a necessary tool for all types of clinical development and/or market approval of new drugs and chemicals. The major change in the last decade is a shift towards more physiologically relevant yet complex and sensitive cell models, like stem cells, and more recently, the shift to human induced pluripotent cells. Stem-cell technology has the potential to revolutionize drug discovery, making models available for primary screens, secondary pharmacology, safety pharmacology, metabolic profiling and toxicity evaluation. The overall aim of DropTech is the development of automated handling processes for stem cells with integrated readout methods, required for the use of stem cells in high-throughput assays such as the embryonic stem cell test (EST). DropTech will result on the one hand in a fully automated screening platform, usable by the industrial partners for reproducible and standardized high-throughput screening services and aggregate production. On the other hand a system that is directly exploitable for industrialization and marketing will be available to perform reliable and fast at least semi-automated screening approaches for customers. Therefore, the complete workflow of the EST, including stem cell expansion, embryoid body formation in hanging drops and transfer to 2D conditions will be automated using robotic and microfluidics systems. This will enable standardized, fast and efficient embryotoxicity screenings reducing the need for animal tests. DropTech will enable testing in a small- and medium-scaled budget accessible for SMEs and academia in the field of biotech and biomedicine. The DropTech platform will have therefore a significant impact on the development of new medication and therapies and will enable personalized medicine approaches as well as - in future - regenerative medicine. DropTech facilitate the use of cell models with highest biological relevance (human pluripotent stem cells) in their native conformation.

Keywords: hanging drop,low material consumption,miniaturization and parallelization
Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance (THINPAD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Spain,France,Italy
Call:  (FP7-HEALTH-2013-INNOVATION-2, 2013)
Start date: 2013-09-01
End date: 2016-08-31
Duration (months): 36.0
Total project cost (EUR): 7451080.8
EU funding (EUR): 5691950.0
Participants: 5
Project status: CLOSED

AIDS is one of the most serious pandemic diseases of the modern era. Although current therapies based on targeting key processes of the HIV replication cycle are potent and selective, several clinical failures are recorded due to the emergence of drug resistance. Hence, there is an urgent need for novel drugs and alternative therapeutic strategies. The objective of the THINPAD proposal is to discover and develop novel anti-HIV agents targeting the HIV nucleocapsid protein(NC), which is one of the most conserved sequence within HIV strains and is highly required for HIV replication, being therefore a primary target to overcome antiretroviral drug-resistance. The proposal originates from the successful FP6 TRIoH project and presents a multidisciplinary approach to develop anti-HIV drugs, ready for early clinical trials, that could be resistant to viral mutation since targeting a highly conserved sequence. The consortium consists of experts in the anti-HIV field which have an extensive expertise in targeting NC. Partner 1 has studied the NC dynamics and discovered small molecule NC modulators by in silico approaches. Partner 2 has developed biophysical methods to monitor the NC functions and the interaction with small molecules. Partner 3 developed a complete approach of biochemistry-, retrovirology- and microscopy-based techniques to monitor NC during HIV assembly, maturation and reverse transcription. Partner 4 is a SME founded by scientists who participated in the development of Raltegravir, which will have a leading role in the project together with Partner 5 (SME) by driving the discovery phase and pre-clinical investigation, favouring the translation of results into innovative applications for health. It is worth noting that the consortium already possesses small molecules endowed with low-micromolar inhibitory activity in cell against HIV and active against resistant strains. Notably, these molecules interact with the NC but not with the usual anti-HIV targets

Keywords: drug resistance,nucleocapsid,antiretroviral,multidisciplinary